News
VBIV
--
0.00%
--
Medulloblastoma Drug Market Growth 2021 Research Key Players, Industry Overview, Share, Size, Supply Chain and Analysis and Forecast 2024
The Express Wire · 12h ago
Global Medulloblastoma Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Medulloblastoma Drug market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 1d ago
Brain Cancer Market Insight, Epidemiology, and Market Forecast Analysis Report
Apr 13, 2021 (AB Digital via COMTEX) -- What is Brain Cancer? A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a...
ABNewswire · 2d ago
VBI’s hepatitis B candidate shows robust response in Phase 1/2 study
Announcing the data from the high-dose cohort of a Phase 1b/2a clinical trial, VBI Vaccines ([[VBIV]] -4.1%) said that its immunotherapeutic candidate, VBI-2601 (BRII-179) generated specific T cell responses in ≥ 50%
Seekingalpha · 4d ago
8-K: VBI Vaccines Inc/BC
(EDGAR Online via COMTEX) -- 0000764195 false VBI Vaccines Inc/BC 0000764195 2021-04-12 2021-04-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
BRIEF-VBI Vaccines Announces Phase 1b/2a Data And Progress Of Hepatitis B Immunotherapeutic Candidate 
reuters.com · 4d ago
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced data and next steps from the high-dose cohort of its Phase 1b/2a clinical study of VBI-...
Business Wire · 4d ago
DJ VBI Vaccines Presents Data from Hepatitis B Study
Dow Jones · 4d ago
VBI Vaccines Announces Data Form Phase 1b/2a Study Of Its Hepatitis B Immunotherapeutic Candidate Showing Robust HBV Specific T Cell Responses In ≥ 50% Of Evaluable Patients
  Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179)
Benzinga · 4d ago
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
Zacks.com · 04/09 11:06
Human cytomegalovirus 65 kDa Phosphoprotein Market Statistics, CAGR, Outlook, and Covid-19 Impact 2021-2027
Market Insight Reports · 04/08 18:19
Does VBI Vaccines (NASDAQ:VBIV) Have A Healthy Balance Sheet?
Simply Wall St. · 04/08 14:21
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
Zacks.com · 04/07 13:34
Medulloblastoma Drug Market Growth, Share, Trends, Demand and Analysis Report Forecast 2021-2027 by
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Medulloblastoma Drug market – global industry size,...
Market Insight Reports · 04/06 19:41
Fauci says government won't mandate vaccine passports
"Anything is on the table. Anything is possible, of course," Dr. Anthony Fauci had said in January regarding a U.S. vaccine passport, though he dispelled the notion in a Politico
Seekingalpha · 04/06 08:58
Influenza A Virus, H3N2 Subtype Infections Drug Market Revenue, Trends, Growth, Share, Size and Forecast 2020-2027 by Ameco Research
pune, India, Tue, 30 Mar 2021 02:46:55 / Comserve Inc. / -- Ameco Research indicates that the Global Influenza A Virus, H3N2 Subtype Infections Drug Market...
Comserve · 03/31 13:09
Human cytomegalovirus 65 kDa Phosphoprotein Market Size,Share, Growth,Trends and Forecast 2020-2027
pune, India, Wed, 24 Mar 2021 02:30:40 / Comserve Inc. / -- The global Human cytomegalovirus 65 kDa Phosphoprotein market is segmented by company, region...
Comserve · 03/24 06:32
Medulloblastoma Drug Market Registering a Strong Growth by 2020-2027 |Ameco Research
pune, India, Tue, 23 Mar 2021 06:53:41 / Comserve Inc. / -- A new research report titled "Global Medulloblastoma Drug Market" successfully exhibits the...
Comserve · 03/23 10:56
The Race for Vaccine Against COVID-19 Variants Heats Up; 3 Stocks to Consider
Let’s talk about the economy and COVID-19. Normally, this is a subject that will dwell on the economic disaster of the past year – the sharp recession last winter, the huge spike in unemployment, the unprecedented surge in government debt. All of these are...
TipRanks · 03/16 16:37
Webull provides a variety of real-time VBIV stock news. You can receive the latest news about VBI Vaccines through multiple platforms. This information may help you make smarter investment decisions.
About VBIV
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).